Get started
Author

Sun Loo

Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy
2020 · Chong Chyn Chua, Andrew W. Roberts, et al. · Journal of Clinical Oncology · 195
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study
2021 · Andrew M. Brunner, Jordi Esteve, et al. · Blood · 106
C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3 -Mutant Leukemia
2023 · Marie Sabatier, Rudy Birsen, et al. · Cancer Discovery · 100
PDF
Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome
2022 · Sun Loo, Richard Dillon, et al. · Blood · 97
PDF
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy
2023 · Jad Othman, Ing S. Tiong, et al. · Blood · 87
PDF
How I treat patients with AML using azacitidine and venetoclax
2024 · Andrew H. Wei, Sun Loo, et al. · Blood · 83
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
2020 · Andrew M. Brunner, Jordi Esteve, et al. · Blood · 69
Phase Ib study of sabatolimab ( MBG453 ), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes
2023 · Andrew M. Brunner, Jordi Esteve, et al. · American Journal of Hematology · 62
PDF
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)
2024 · Ing Soo Tiong, Devendra K. Hiwase, et al. · Journal of Clinical Oncology · 35
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG
2023 · Sun Loo, Andrew W. Roberts, et al. · Blood · 35
PDF
Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication
2023 · Ing S. Tiong, Sun Loo · International Journal of Molecular Sciences · 34
PDF
Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A- rearranged acute myeloid leukemia
2024 · Sun Loo, Nicola Potter, et al. · Blood · 19
PDF
Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)
2020 · Andrew H Wei, Glen A Kennedy, et al. · Blood · 18
ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial
2022 · Andrew H Wei, Harry J Iland, et al. · Blood · 17
Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT)
2025 · Chong Chyn Chua, Sun Loo, et al. · Blood Advances · 11
PDF
A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia
2022 · Ing S Tiong, Devendra Hiwase, et al. · Blood · 11
Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose
2020 · Andrew H. Wei, Jordi Esteve, et al. · Blood · 11
Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A-rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial
2024 · Sun Loo, Harry Iland, et al. · Blood · 10
PDF
Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents
2021 · Andrew M. Brunner, Elie Traer, et al. · Blood · 9
High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial
2022 · Chong Chyn Chua, Sun Loo, et al. · Blood · 7
MDS-420: Sabatolimab Plus Hypomethylating Agents (HMAs) in Patients with High-/Very High-risk Myelodysplastic Syndrome (HR/vHR-MDS) and Newly Diagnosed Acute Myeloid Leukemia (ND-AML): Subgroup Analysis of a Phase 1 Study
2021 · Guillermo Garcia-Manero, Andrew H. Wei, et al. · Clinical Lymphoma Myeloma & Leukemia · 6
ELN-DAVID recommendations for NGS-based FLT3 -ITD MRD testing for patients with acute myeloid leukemia
2026 · Christopher S. Hourigan, Lisanne Beugelink, et al. · Blood · 5
PDF
Venetoclax Has Potent Efficacy in NPM1 mutated AML with Acquired Resistance Associated with Either Perturbed Pro-Survival Signalling or NPM1 wild-Type Populations
2023 · Chong Chyn Chua, Natasha Anstee, et al. · Blood · 5
A Phase-Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT3-ITD and CBL-Mutant Acute Myeloid Leukemia (PON-AZA study)
2021 · David Kipp, Sun Loo, et al. · Blood · 5
CD74 Antibody Conjugated to an MCL1 Inhibitor (S227928) Combines Synergistically with Venetoclax to Enhance Killing of Acute Myeloid Leukemia
2024 · Donia M. Moujalled, Giovanna Pomilio, et al. · Blood · 2
Works count: 143
Citation count: 1,048
H-index: 14
I10-index: 18
Year
Topic
Type